ea0090ep397 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023
Sakar Kenan
, Avci Melek
, Akbaba Gulhan
, Cinar Nese
Introduction: Sodium/glucose co-transporter 2 (SGLT2) inhibitors are novel oral hypoglycemic agents that are increasingly used in the management of type 2 diabetes mellitus (T2DM). They are now recommended as second-line pharmacotherapy (in conjunction with metformin) in patients with type 2 diabetes and established atherosclerotic heart disease, heart failure or chronic kidney disease due to their favourable effects on cardiovascular and renal outcomes. We report a case of a ...